Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

被引：4
|
作者：
Chen, Ning [2 ,3 ]
Xu, Xiaoling [1 ]
Fan, Yun [1 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷
基金：
中国国家自然科学基金;
关键词：
biomarker; immune checkpoint inhibitor; immunotherapy; oesophageal squamous cell carcinoma; PD-L1; OPEN-LABEL; TUMOR MICROENVIRONMENT; POOR-PROGNOSIS; PHASE-II; CANCER; NIVOLUMAB; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAMRELIZUMAB; EXPRESSION;
D O I：
10.1177/17588359231189420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
引用
收藏
页数：18
相关论文
共 50 条
  • [41] Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going
    Sun, Chen
    Espana, Sofia
    Buges, Cristina
    Layos, Laura
    Hierro, Cinta
    Manzano, Jose Luis
    CLINICAL COLORECTAL CANCER, 2022, 21 (02) : 71 - 79
  • [42] Personalized medicine in gastric cancer: Where are we and where are we going?
    Jacome, Alexandre A.
    Coutinho, Anelisa K.
    Lima, Enaldo M.
    Andrade, Aline C.
    dos Santos, Jose Sebastiao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (03) : 1160 - 1171
  • [43] Molecular targeted agents-where we are and where we are going
    Yan, Li
    CHINESE JOURNAL OF CANCER, 2013, 32 (05) : 225 - 232
  • [44] Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
    Jin, Zhao
    Cao, Yanshuo
    Lu, Zhihao
    Liu, Chang
    Shen, Lin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [45] THE NEUROBIOLOGY OF ADDICTION: WHERE WE HAVE BEEN AND WHERE WE ARE GOING
    Koob, George F.
    Simon, Eric J.
    JOURNAL OF DRUG ISSUES, 2009, 39 (01) : 115 - 132
  • [46] PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
    Li, Yiyang
    Wu, Yike
    Gao, Sihan
    Sun, Tao
    Jiang, Chen
    JOURNAL OF CONTROLLED RELEASE, 2025, 378 : 116 - 144
  • [47] Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
    Bossi, Paolo
    Lorini, Luigi
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11
  • [48] Fertility Preservation in Children and Adolescents: Where We Are and Where We Are Going
    Vogt, Campbell
    Malhotra, Neha R.
    CURRENT UROLOGY REPORTS, 2024, 25 (07) : 133 - 140
  • [49] Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation
    Liu, Shixian
    Dou, Lei
    Li, Shunping
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [50] Multimodal treatment of gastric cancer in the west: Where are we going?
    Marrelli, Daniele
    Polom, Karol
    de Manzoni, Giovanni
    Morgagni, Paolo
    Baiocchi, Gian Luca
    Roviello, Franco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (26) : 7954 - 7969
12345